News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Accepts Resubmission of Eisai Inc. (ESALF.PK)'s Perampanel New Drug Application


3/6/2012 6:46:22 AM

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai’s resubmission of the New Drug Application (NDA) for perampanel (E2007), an investigational drug, for the treatment of partial-onset seizures associated with epilepsy. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target date of October 22, 2012.

Read at BioSpace.com


comments powered by Disqus
   
Epilepsy

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES